Sign in with Google
bearish
Samsung BioLogics and Biogen: Who Had Control?
429 Views04 May 2018 14:02
The controversy surrounding Samsung Biologics Co., Ltd (207940 KS) 's booking of a fair value gain in 2015 relates to their claim of a "loss of...
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 4-minute read)
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Index Treatment of Sony (6758 JP)'s Spinoff of the Financial Services Business
- BYD (1211 HK/002594 CH) - Key Takeaways from AGM
- Xtalpi US$860m IPO Lockup Expiry - Last of the Lockup Release with Nearly All Shares in CCASS Now
- Austal (ASB AU): A Hanwha Bid Is Back In Play
- With Us (9696 JP): NSSK’s JPY3,237 Tender Offer
Top Unpaywalled Insights
More »- Bearishness Persist in Soybeans Despite Rebound Hopes
- Curator's Cut: The Next Labubu, Crypto Equities and Tracking APAC Buybacks
- [IO Technicals 2025/23] Bearish Momentum Persists
- VEON US: Pakistan Towers Sale Frees Capital for Digital Growth in Core Market Ahead of Ukraine IPO
- Advanced Look: Navigating the New Macro Landscape Through Quantitative Alpha Generation Strategies
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Last Week in Event SPACE: Samsung Biologics, Shire, Lotte, Mitula, JSW, Nisshinbo12 May 2018
- FSS Vs. Samsung BioLogics - Latest Situation Update09 May 2018
- Samsung BioLogics - Market Sentiment Assessment05 May 2018
- Samsung Biologics' Accounting Violation's Impact on Samsung C&T and Rest of the Korean Pharmas01 May 2018
- A Conversation with Biogen12 Apr 2018
x